Equities Analysts Issue Forecasts for CRSP FY2027 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Stock analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a research note issued on Tuesday, March 4th. Zacks Research analyst R. Department expects that the company will post earnings per share of ($4.62) for the year. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%.

Several other analysts have also issued reports on CRSP. Morgan Stanley upped their price target on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research report on Friday, February 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Barclays raised their target price on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. HC Wainwright reissued a “buy” rating and set a $65.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Finally, Evercore ISI raised CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and raised their price objective for the company from $60.00 to $99.00 in a research report on Friday, February 14th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, CRISPR Therapeutics has a consensus rating of “Hold” and a consensus price target of $74.40.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP opened at $43.45 on Wednesday. CRISPR Therapeutics has a 52-week low of $36.52 and a 52-week high of $83.50. The company has a market cap of $3.73 billion, a P/E ratio of -9.94 and a beta of 1.67. The stock’s 50-day simple moving average is $42.57 and its 200 day simple moving average is $45.86.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of the company’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the sale, the chief executive officer now directly owns 171,613 shares of the company’s stock, valued at $9,473,037.60. This represents a 9.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director John Greene acquired 7,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 26th. The stock was acquired at an average cost of $44.85 per share, with a total value of $313,950.00. Following the completion of the acquisition, the director now owns 7,000 shares in the company, valued at $313,950. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Several hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of CRISPR Therapeutics by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,080 shares of the company’s stock worth $146,000 after acquiring an additional 545 shares during the last quarter. Pinnacle Associates Ltd. purchased a new stake in CRISPR Therapeutics during the third quarter valued at about $188,000. Privium Fund Management B.V. lifted its stake in CRISPR Therapeutics by 11.0% during the third quarter. Privium Fund Management B.V. now owns 30,347 shares of the company’s stock worth $1,426,000 after purchasing an additional 3,000 shares during the last quarter. Axxcess Wealth Management LLC boosted its holdings in shares of CRISPR Therapeutics by 3.3% in the 3rd quarter. Axxcess Wealth Management LLC now owns 10,271 shares of the company’s stock worth $483,000 after purchasing an additional 330 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D increased its position in shares of CRISPR Therapeutics by 16.8% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 40,341 shares of the company’s stock valued at $1,895,000 after purchasing an additional 5,803 shares during the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.